Exploiting Mucosal Immunity for Antiviral Vaccines

Annual Review of Immunology

Volumn 34, Issue , 2016, Pages 575-608

  Iwasaki, Akiko ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell mediated immunity; Herpes simplex virus; HIV 1 AIDS; Influenza virus; Neutralizing antibody; Tissue resident memory; Viral evasion

Indexed keywords

HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; NON NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

B LYMPHOCYTE; CELLULAR IMMUNITY; GENITAL HERPES; GERIATRIC DISORDER; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 2; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; MEMORY CELL; MEMORY T LYMPHOCYTE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION; ANIMAL; COMPARATIVE STUDY; IMMUNE EVASION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; ORTHOMYXOVIRIDAE; SIMPLEXVIRUS; VIRUS DISEASES;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HIV; HUMANS; IMMUNE EVASION; IMMUNITY, MUCOSAL; IMMUNOLOGIC MEMORY; ORTHOMYXOVIRIDAE; SIMPLEXVIRUS; VIRAL VACCINES; VIRUS DISEASES;

EID: 84969857239     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032414-112315     Document Type: Review

References (236)

1. PalmNW,Medzhitov R. 2009. Pattern recognition receptors and control of adaptive immunity. Immunol. Rev. 227:221-33
2. Iwasaki A, Medzhitov R. 2010. Regulation of adaptive immunity by the innate immune system. Science 327:291-95
3. Kanno Y, Vahedi G, Hirahara K, Singleton K, O'Shea JJ. 2012. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. Annu. Rev. Immunol. 30:707-31
4. Banchereau J, Steinman RM. 1998. Dendritic cells and the control of immunity. Nature 392:245-52
5. Kawai T, Akira S. 2010. The role of pattern-recognition receptors in innate immunity: update on Tolllike receptors. Nat. Immunol. 11:373-84
6. Liniger M, Zuniga A, Naim HY. 2007. Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 6:255-66
7. IwasakiA,Medzhitov R. 2015. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16:343-53
8. Virgin HW, Wherry EJ, Ahmed R. 2009. Redefining chronic viral infection. Cell 138:30-50
9. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. 2012. Diversity, stability and resilience of the human gut microbiota. Nature 489:220-30
10. Iwasaki A. 2007. Mucosal dendritic cells. Annu. Rev. Immunol. 25:381-418
11. Linden SK, Sutton P, Karlsson NG, Korolik V, McGuckin MA. 2008. Mucins in the mucosal barrier to infection. Mucosal Immunol. 1:183-97
12. Cone RA. 2009. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61:75-85
13. Wilks J, BeilinsonH,Golovkina TV. 2013. Dual role of commensal bacteria in viral infections. Immunol. Rev. 255:222-29
14. Haase AT. 2010. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464:217-23
15. Frazer IH. 2004. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 4:46-54
16. Moody CA, Laimins LA. 2010. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10:550-60
17. GillietM, Cao W, Liu YJ. 2008. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 8:594-606
18. Goubau D, Deddouche S, Reis e Sousa C. 2013. Cytosolic sensing of viruses. Immunity 38:855-69
19. Hou B, Reizis B, DeFranco AL. 2008. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and-extrinsic mechanisms. Immunity 29:272-82
20. Rath T, Baker K, Pyzik M, Blumberg RS. 2015. Regulation of immune responses by the neonatal Fc receptor and its therapeutic implications. Front. Immunol. 5:664
21. Hangartner L, Zinkernagel RM, Hengartner H. 2006. Antiviral antibody responses: the two extremes of a wide spectrum. Nat. Rev. Immunol. 6:231-43
22. Para MF, Goldstein L, Spear PG. 1982. Similarities and differences in the Fc-binding glycoprotein (gE) of herpes simplex virus types 1 and 2 and tentative mapping of the viral gene for this glycoprotein. J. Virol. 41:137-44
23. Awasthi S, Huang J, Shaw C, Friedman HM. 2014. Blocking HSV-2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes. J. Virol. 88:8421-32
24. Ackerman ME, Alter G. 2013. Opportunities to exploit non-neutralizingHIV-specific antibody activity. Curr. HIV Res. 11:365-77
25. Lubinski J, Wang L, MastellosD, Sahu A, Lambris JD, Friedman HM. 1999. In vivo role of complementinteracting domains of herpes simplex virus type 1 glycoprotein gC. J. Exp. Med. 190:1637-46
26. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-12
27. Zinkernagel RM. 1996. Immunology taught by viruses. Science 271:173-78
28. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, et al. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225-34
29. MedzhitovR, Schneider DS, SoaresMP. 2012. Disease tolerance as a defense strategy. Science 335:936-41
30. Raberg L, Sim D, Read AF. 2007. Disentangling genetic variation for resistance and tolerance to infectious diseases in animals. Science 318:812-14
31. Ayres JS, Schneider DS. 2012. Tolerance of infections. Annu. Rev. Immunol. 30:271-94
32. Zeitlin L, Cone RA, Moench TR, Whaley KJ. 2000. Preventing infectious disease with passive immunization. Microbes Infect. 2:701-8
33. Franco MA, Angel J, Greenberg HB. 2006. Immunity and correlates of protection for rotavirus vaccines. Vaccine 24:2718-31
34. Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. 2013. A systematic review of antirotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J. Infect. Dis. 208:284-94
35. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, et al. 2003. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J. Natl. Cancer Inst. 95:1128-37
36. Frazer I. 2007. Correlating immunity with protection for HPV infection. Int. J. Infect. Dis. 11(Suppl. 2):S10-16
37. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, et al. 2006. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24:5571-83
38. Leon B, Ballesteros-Tato A,Misra RS,WojciechowskiW, Lund FE. 2012. Unraveling effector functions of B cells during infection: the hidden world beyond antibody production. Infect. Disord. Drug Targets 12:213-21
39. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, et al. 2008. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis. 197:825-35
40. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, et al. 2009. Varicella-zoster virusspecific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J. Infect. Dis. 200:1068-77
41. Gilbert PB, Gabriel EE, Miao X, Li X, Su SC, et al. 2014. Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve. J. Infect. Dis. 210:1573-81
42. Parr EL, Parr MB. 1998. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J. Virol. 72:5137-45
43. Belec L, Tevi-Benissan C, Lu XS, Prazuck T, Pillot J. 1995. Local synthesis of IgG antibodies to HIV within the female and male genital tracts during asymptomatic and pre-AIDS stages of HIV infection. AIDS Res. Hum. Retrovir. 11:719-29
44. Belec L, Dupre T, Prazuck T, Tevi-Benissan C, Kanga JM, et al. 1995. Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection. J. Infect. Dis. 172:691-97
45. BomselM,Tudor D, Drillet A-S, Alfsen A,Ganor Y, et al. 2011. Immunization withHIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34:269-80
46. Li Q, Zeng M, Duan L, Voss JE, Smith AJ, et al. 2014. Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J. Immunol. 193:3113-25
47. Shin H, Iwasaki A. 2013. Tissue-resident memory T cells. Immunol. Rev. 255:165-81
48. Mueller SN, Gebhardt T, Carbone FR, Heath WR. 2012. Memory T cell subsets, migration patterns, and tissue residence. Annu. Rev. Immunol. 31:137-61
49. Cauley LS, Lefrancois L. 2013. Guarding the perimeter: protection of the mucosa by tissue-resident memory T cells. Mucosal Immunol. 6:14-23
50. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. 2009. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10:524-30
51. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. 2010. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat. Med. 16:224-27
52. Hogan RJ, Zhong W, Usherwood EJ, Cookenham T, Roberts AD, Woodland DL. 2001. Protection from respiratory virus infections can be mediated by antigen-specific Cd4+ T cells that persist in the lungs. J. Exp. Med. 193:981-86
53. Liang S,Mozdzanowska K, Palladino G, Gerhard W. 1994. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1653-61
54. Wu T, Hu Y, Lee YT, Bouchard KR, Benechet A, et al. 2014. Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection. J. Leukoc. Biol. 95:215-24
55. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrancois L, Farber DL. 2011. Cutting edge: Tissueretentive lungmemoryCD4Tcells mediate optimal protection to respiratory virus infection. J. Immunol. 187:5510-14
56. Iijima N, Iwasaki A. 2014. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science 346:93-98
57. Farber DL, YudaninNA, Restifo NP. 2014. Human memory T cells: generation, compartmentalization and homeostasis. Nat. Rev. Immunol. 14:24-35
58. Thome JJ, Yudanin N, Ohmura Y, Kubota M, Grinshpun B, et al. 2014. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell 159:814-28
59. Schiffer JT, Abu-Raddad L,MarkKE, Zhu J, Selke S, et al. 2010. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. PNAS 107:18973-78
60. Zhu J, Peng T, Johnston C, Phasouk K, Kask AS, et al. 2013. Immune surveillance by CD8αα+ skinresident T cells in human herpes virus infection. Nature 497:494-97
61. Schiffer JT, SwanD, Sallaq RA,Magaret A, Johnston C, et al. 2013. Rapid localized spread and immunologic containment define herpes simplex virus-2 reactivation in the human genital tract. eLife 2:e00288
62. Zhu J,KoelleDM,Cao J, Vazquez J,HuangML,et al. 2007. Virus-specificCD8+ Tcells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 204:595-603
63. Schiffer JT. 2013. Mucosal HSV-2 specific CD8+ T-cells represent containment of prior viral shedding rather than a correlate of future protection. Front. Immunol. 4:209
64. Fleming DT, McQuillan GM, Johnson RE,Nahmias AJ, Aral SO, et al. 1997. Herpes simplex virus type 2 in the United States, 1976 to 1994. N. Engl. J. Med. 337:1105-11
65. Buchman TG, Roizman B, Nahmias AJ. 1979. Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA. J. Infect. Dis. 140:295-304
66. Schmidt OW, Fife KH, Corey L. 1984. Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J. Infect. Dis. 149:645-46
67. Sakaoka H, Aomori T, Gouro T, Kumamoto Y. 1995. Demonstration of either endogenous recurrence or exogenous reinfection by restriction endonuclease cleavage analysis of herpes simplex virus from patients with recrudescent genital herpes. J. Med. Virol. 46:387-96
68. Awasthi S, Friedman HM. 2014. Status of prophylactic and therapeutic genital herpes vaccines. Curr. Opin. Virol. 6:6-12
69. Hofstetter AM, Rosenthal SL, Stanberry LR. 2014. Current thinking on genital herpes. Curr. Opin. Infect. Dis. 27:75-83
70. Dropulic LK, Cohen JI. 2012. The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev. Vaccines 11:1429-40
71. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, et al. 1999. Recombinant glycoprotein vaccine for the prevention of genitalHSV-2 infection: two randomized controlled trials. JAMA 282:331-40
72. Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, Pierre C, et al. 2005. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin. Infect. Dis. 40:1271-81
73. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, et al. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-61
74. Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, et al. 2014. Correlate of immune protection against HSV-1 genital disease in vaccinated women. J. Infect. Dis. 209:828-36
75. Para MF, Parish ML, Noble AG, Spear PG. 1985. Potent neutralizing activity associated with antiglycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions. J. Virol. 55:483-88
76. WhaleyKJ, Zeitlin L, Barratt RA,HoenTE, Cone RA. 1994. Passive immunization of the vagina protects mice against vaginal transmission of genital herpes infections. J. Infect. Dis. 169:647-49
77. Sherwood JK, Zeitlin L, Whaley KJ, Cone RA, Saltzman M. 1996. Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Nat. Biotechnol. 14:468-71
78. McDermott MR, Brais LJ, Evelegh MJ. 1990. Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2. J. Gen. Virol. 71:1497-504
79. Parr EL, Bozzola JJ, Parr MB. 1998. Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus. J. Reprod. Immunol. 38:15-30
80. Chu CF, Meador MG, Young CG, Strasser JE, Bourne N, Milligan GN. 2008. Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc and gamma receptor-dependent and-independent mechanisms. J. Reprod. Immunol. 78:58-67
81. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. 2000. Protection of macaques against vaginal transmission of a pathogenicHIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:207-10
82. Nagashunmugam T, Lubinski J, Wang L, Goldstein LT, Weeks BS, et al. 1998. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J. Virol. 72:5351-59
83. Lubinski JM, Lazear HM, Awasthi S, Wang F, Friedman HM. 2011. The herpes simplex virus 1 IgG Fc receptor blocks antibody-mediated complement activation and antibody-dependent cellular cytotoxicity in vivo. J. Virol. 85:3239-49
84. Hook LM, Lubinski JM, JiangM, PangburnMK, Friedman HM. 2006. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulinM antibody. J. Virol. 80:4038-46
85. Gewurz BE, Gaudet R, Tortorella D, Wang EW, Ploegh HL. 2001. Virus subversion of immunity: a structural perspective. Curr. Opin. Immunol. 13:442-50
86. Ashley RL, Crisostomo FM,DossM, Sekulovich RE, Burke RL, et al. 1998. Cervical antibody responses to a herpes simplex virus type 2 glycoprotein subunit vaccine. J. Infect. Dis. 178:1-7
87. Zhu J,Hladik F, Woodward A, Klock A, Peng T, et al. 2009. Persistence ofHIV-1 receptor-positive cells afterHSV-2 reactivation is a potential mechanism for increasedHIV-1 acquisition. Nat. Med. 15:886-92
88. Schiffer JT, Abu-Raddad L,MarkKE, Zhu J, Selke S, et al. 2010. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. PNAS 107:18973-78
89. Peng T, Zhu J, Phasouk K, Koelle DM, Wald A, Corey L. 2012. An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection. J. Virol. 86:10587-96
90. Zhu J, Peng T, Johnston C, Phasouk K, Kask AS, et al. 2013. Immune surveillance by CD8αα+ skinresident T cells in human herpes virus infection. Nature 497:494-97
91. Shin H, Iwasaki A. 2012. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491:463-67
92. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, et al. 2012. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. PNAS 109:7037-42
93. Iijima N, Iwasaki A. 2014. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science 346:93-98
94. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, et al. 2012. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J. Virol. 86:4586-98
95. Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, et al. 2011. Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone. J. Virol. 85:10472-86
96. Awasthi S, Lubinski JM, Friedman HM. 2009. Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine. Vaccine 27:6845-53
97. Schenkel JM, Fraser KA, Vezys V, Masopust D. 2013. Sensing and alarm function of resident memory CD8+ T cells. Nat. Immunol. 14:509-13
98. UNAIDS, WHO (U.N. Prog. HIV/AIDS, World Health Organ.). 2007. AIDS Epidemic Update 2007. Geneva: UNAIDS
99. WHO (World Health Organ.). 2008. Report on the Global AIDS Epidemic. Geneva:WHO
100. Altfeld M, Allen TM, Yu XG, JohnstonMN, Agrawal D, et al. 2002. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 420:434-39
101. Walker BD, Yu XG. 2013. Unravelling the mechanisms of durable control ofHIV-1. Nat. Rev. Immunol. 13:487-98
102. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, et al. 2010. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-57
103. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, et al. 2008. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197:563-71
104. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, et al. 2000. HLA B and z ast 5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. PNAS 97:2709-14
105. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. 2007. A whole-genome association study of major determinants for host control of HIV-1. Science 317:944-47
106. Pelak K, Goldstein DB, Walley NM, Fellay J, Ge D, et al. 2010. Host determinants of HIV-1 control in African Americans. J. Infect. Dis. 201:1141-49
107. Limou S, Le Clerc S, Coulonges C, CarpentierW, Dina C, et al. 2009. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J. Infect. Dis. 199:419-26
108. CarringtonM,NelsonGW,Martin MP, Kissner T, Vlahov D, et al. 1999.HLAandHIV-1 heterozygote advantage and B and z ast 35-Cw and z ast 04 disadvantage. Science 283:1748-52
109. Kaslow RA, CarringtonM, Apple R, Park L,Munoz A, et al. 1996. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2:405-11
110. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, et al. 2009. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113:3978-89
111. Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, et al. 2010. Perforin expression directly ex vivo by HIV-specific CD8+ T-cells is a correlate of HIV elite control. PLOS Pathog. 6:e1000917
112. Killian MS, Johnson C, Teque F, Fujimura S, Levy JA. 2011. Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells. J. Virol. 85:1696-705
113. Akinsiku OT, Bansal A, Sabbaj S, Heath SL, Goepfert PA. 2011. Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression. J. Acquir. Immune Defic. Syndr. 58:132-40
114. Bailey JR, LassenKG, Yang HC,Quinn TC, Ray SC, et al. 2006. Neutralizing antibodies do notmediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. J. Virol. 80:4758-70
115. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincelette J, et al. 2001. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21:227-33
116. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, et al. 1996. HIV-1 gp120-specific antibodydependent cell-mediated cytotoxicity correlates with rate of disease progression. J. Immunol. 157:2168-73
117. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, et al. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:897-906
118. Dalgleish A, Sinclair A, Steel M, Beatson D, Ludlam C, Habeshaw J. 1990. Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort. Clin. Exp. Immunol. 81:5-10
119. Smalls-Mantey A,Doria-Rose N, Klein R, Patamawenu A, Migueles SA, et al. 2012. Antibody-dependent cellular cytotoxicity against primaryHIV-infectedCD4+ Tcells is directly associated with themagnitude of surface IgG binding. J. Virol. 86:8672-80
120. MiyazawaM, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, Clerici M. 2009. The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 23:161-75
121. Erickson AL, Willberg CB, McMahan V, Liu A, Buchbinder SP, et al. 2008. Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specificCD8+ T-cell responseswhich can be defined to the epitope level. Clin. Vaccine Immunol. 15:1745-48
122. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, et al. 1994. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 271:42-46
123. Pinto LA, Sullivan J, Berzofsky JA, Clerici M, Kessler HA, et al. 1995. ENV-specific cytotoxicTlymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Investig. 96:867-76
124. Rowland-Jones SL, Dong T, Fowke KR, Kimani J, Krausa P, et al. 1998. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Investig. 102:1758-65
125. Stranford SA, Skurnick J, Louria D, Osmond D, Chang SY, et al. 1999. Lack of infection inHIV-exposed individuals is associated with a strong CD8+ cell noncytotoxic anti-HIV response. PNAS 96:1030-35
126. Ritchie AJ, Campion SL, Kopycinski J,Moodie Z,Wang ZM, et al. 2011. Differences inHIV-specific T cell responses between HIV-exposed and-unexposed HIV-seronegative individuals. J. Virol. 85:3507-16
127. Begaud E, Chartier L, Marechal V, Ipero J, Leal J, et al. 2006. Reduced CD4 T cell activation and in vitro susceptibility to HIV-1 infection in exposed uninfected Central Africans. Retrovirology 3:35
128. JennesW, Evertse D, Borget MY, Vuylsteke B, Maurice C, et al. 2006. Suppressed cellular alloimmune responses in HIV-exposed seronegative female sex workers. Clin. Exp. Immunol. 143:435-44
129. CardCM, McLaren PJ, WachihiC, Kimani J, Plummer FA, FowkeKR. 2009. Decreased immune activation in resistance to HIV-1 infection is associated with an elevated frequency of CD4+CD25+FOXP3+ regulatory T cells. J. Infect. Dis. 199:1318-22
130. Camara M, Dieye TN, Seydi M, Diallo AA, Fall M, et al. 2010. Low-level CD4+ T cell activation in HIV-exposed seronegative subjects: influence of gender and condom use. J. Infect. Dis. 201:835-42
131. Koning FA,Otto SA,HazenbergMD, Dekker L, Prins M, et al. 2005. Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J. Immunol. 175:6117-22
132. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, et al. 1997. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3:1250-57
133. Mestecky J, Wright PF, Lopalco L, Staats HF, Kozlowski PA, et al. 2011. Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women. AIDS Res. Hum. Retrovir. 27:469-86
134. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, et al. 2003. Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J. Immunol. 171:5663-67
135. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. 2006. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-71
136. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-65
137. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-905
138. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebocontrolled, test-of-concept trial. Lancet 372:1881-93
139. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-20
140. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. 2012. Immunecorrelates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366:1275-86
141. Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-47
142. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, et al. 2012. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. PNAS 109:18921-25
143. Trkola A, Kuster H, Rusert P, Wyl V, Leemann C, et al. 2008. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J. Virol. 82:1591-99
144. Nishimura Y, IgarashiT,Haigwood N, Sadjadpour R, Plishka RJ, et al. 2002. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76:2123-30
145. Mascola JR. 2002. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20:1922-25
146. Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, et al. 2014. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514:642-45
147. Kwong PD, Mascola JR, Nabel GJ. 2011. Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 1:a007278
148. Walker LM, Burton DR. 2010. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 22:358-66
149. Haynes BF, Kelsoe G, Harrison SC, Kepler TB. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30:423-33
150. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-61
151. Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, et al. 2010. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467:591-95
152. Haynes BF, Fleming J, Clair EW, Katinger H, Stiegler G, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-8
153. Meffre E. 2011. The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann. N. Y. Acad. Sci. 1246:1-10
154. Doria-Rose NA, Schramm CA, Gorman J,Moore PL, Bhiman JN, et al. 2014. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509:55-62
155. Wang S, Mata-Fink J, Kriegsman B,HansonM, Irvine DJ, et al. 2015. Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell 160:785-97
156. Tregoning JS, Buffa V, Oszmiana A, Klein K, Walters AA, Shattock RJ. 2013. A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice. PLOS ONE 8:e80559
157. Greene JM, Lhost JJ, Burwitz BJ, Budde ML, Macnair CE, et al. 2010. Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239 nef-vaccinated macaques suppress SIVmac239 replication ex vivo. J. Virol. 84:3362-72
158. Genesca M, McChesney MB, Miller CJ. 2009. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. J. Intern. Med. 265:67-77
159. Sasikala-Appukuttan AK, Kim HO, KinzelNJ, Hong JJ, Smith AJ, et al. 2013. Location and dynamics of the immunodominantCD8Tcell response to SIV nef immunization and SIVmac251 vaginal challenge. PLOS ONE 8:e81623
160. Hansen SG, Ford JC, LewisMS, Ventura AB, Hughes CM, et al. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-27
161. Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, et al. 2013. Immune clearance of highly pathogenic SIV infection. Nature 502:100-4
162. WHO (World Health Organ.). 2014. Influenza Fact Sheet. http://www.who.int/mediacentre/ factsheets/fs211/en
163. Palese P. 2004. Influenza: old and new threats. Nat. Med. 10:S82-87
164. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. 2010. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med. Res. Methodol. 10:18
165. Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum haemagglutinationinhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. 70:767-77
166. McMichael AJ, Gotch FM, NobleGR, Beare PA. 1983. Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309:13-17
167. Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, et al. 2011. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J. 30:1081-85
168. McElhaney JE. 2011. Influenza vaccine responses in older adults. Ageing Res. Rev. 10:379-88
169. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, et al. 2012. Preexisting influenzaspecific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18:274-80
170. Strutt TM,McKinstry KK, Dibble JP, Winchell C, Kuang Y, et al. 2010. Memory CD4+ T cells induce innate responses independently of pathogen. Nat. Med. 16:558-64
171. Sridhar S, Begom S, Bermingham A, Hoschler K, AdamsonW, et al. 2013. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19:1305-12
172. Yewdell JW. 2013. To dream the impossible dream: universal influenza vaccination. Curr. Opin. Virol. 3:316-21
173. Krammer F, Palese P, Steel J. 2014. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr. Top. Microbiol. Immunol. 386:301-21
174. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, et al. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850-56
175. Sagawa H, Ohshima A, Kato I, Okuno Y, Isegawa Y. 1996. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J. Gen. Virol. 77(Pt. 7):1483-87
176. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, et al. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1:e00018-10
177. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87:6542-50
178. Margine I, Krammer F, Hai R, Heaton NS, Tan GS, et al. 2013. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87:10435-46
179. Krammer F, Hai R, Yondola M, Tan GS, Leyva-Grado VH, et al. 2014. Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 88:3432-42
180. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, et al. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060-64
181. Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, et al. 2013. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat. Immunol. 14:1266-76
182. Lingwood D, McTamney PM, Yassine HM,Whittle JR, Guo X, et al. 2012. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489:566-70
183. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, et al. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289:179-86
184. Shaw AC, Goldstein DR, Montgomery RR. 2013. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13:875-87
185. Weng N-p. 2006. Aging of the immune system: How much can the adaptive immune system adapt? Immunity 24:495-99
186. Maue AC, Yager EJ, Swain SL, Woodland DL, Blackman MA, Haynes L. 2009. T-cell immunosenescence: lessons learned from mouse models of aging. Trends Immunol. 30:301-5
187. Franceschi C, Bonaf eM, Valensin S, Olivieri F, De Luca M, et al. 2000. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 908:244-54
188. Murasko DM, Jiang J. 2005. Response of aged mice to primary virus infections. Immunol. Rev. 205:285-96
189. Stout-Delgado HW, Yang X,Walker WE, Tesar BM, Goldstein DR. 2008. Aging impairs IFN regulatory factor 7 upregulation in plasmacytoid DCs during TLR9 activation. J. Immunol. 181:6747-56
190. Jefferson T, Rivetti D, Rivetti A, RudinM, Di Pietrantonj C, Demicheli V. 2005. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366:1165-74
191. McElhaney JE, Xie D, Hager WD, Barry MB, Wang Y, et al. 2006. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176:6333-39
192. McElhaney JE, Ewen C, Zhou X, Kane KP, Xie D, et al. 2009. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 27:2418-25
193. Wagar LE, Gentleman B, Pircher H, McElhaney JE, Watts TH. 2011. Influenza-specific T cells from older people are enriched in the late effector subset and their presence inversely correlates with vaccine response. PLOS ONE 6:e23698
194. Panda A, Qian F, Mohanty S, van Duin D, Newman FK, et al. 2010. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol. 184:2518-27
195. Allman D, Miller JP. 2005. B cell development and receptor diversity during aging. Curr. Opin. Immunol. 17:463-67
196. Falsey AR,Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. 2009. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis. 200:172-80
197. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, et al. 2008. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198:650-58
198. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. 2012. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev. Vaccines 11:985-94
199. Shaw AC, Goldstein DR, Montgomery RR. 2013. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 13:875-87
200. Qian F, Wang X, Zhang L, Chen S, Piecychna M, et al. 2012. Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly. Aging Cell 11:104-10
201. Leng J, Stout-Delgado HW, Kavita U, Jacobs A, Tang J, et al. 2011. Efficacy of a vaccine that links viral epitopes to flagellin in protecting aged mice from influenza viral infection. Vaccine 29:8147-55
202. Sun K, Ye J, Perez DR, Metzger DW. 2011. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 2009 influenza and secondary bacterial infections. J. Immunol. 186:987-93
203. Slutter B, Pewe LL, Lauer P, Harty JT. 2013. Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine. J. Immunol. 190:3854-58
204. Ambrose CS, LukeC,Coelingh K. 2008. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir. Viruses 2:193-202
205. Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, et al. 2012. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity ofMVA-NP+M1 in adults aged over 50 years. PLOS ONE 7:e48322
206. Behzad H, Huckriede AL, Haynes L, Gentleman B, Coyle K, et al. 2012. GLA-SE, a synthetic Tolllike receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 205:466-73
207. Beadling C, Slifka MK. 2004. How do viral infections predispose patients to bacterial infections? Curr. Opin. Infect. Dis. 17:185-91
208. McCullers JA. 2006. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19:571-82
209. Jamieson AM, Pasman L, Yu S, Gamradt P, Homer RJ, et al. 2013. Role of tissue protection in lethal respiratory viral-bacterial coinfection. Science 340:1230-34
210. Nalin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, et al. 1993. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J. Hepatol. 18(Suppl. 2):S51-55
211. Jack AD, Hall AJ, Maine N,Mendy M, Whittle HC. 1999. What level of hepatitis B antibody is protective? J. Infect. Dis. 179:489-92
212. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. 2005. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23:5205-11
213. Chen RT,Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, et al. 1990. Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162:1036-42
214. Samb B, Aaby P, Whittle HC, Seck AM, Rahman S, et al. 1995. Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr. Infect. Dis. J. 14:203-9
215. WHO (World Health Organ.). 1993. The Immunological Basis for Immunization Series. Geneva:WHO
216. Weibel RE, Buynak EB, McLean AA, Hilleman MR. 1975. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 56:380-87
217. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. 1990. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J. Infect. Dis. 162:1291-97
218. Marine WM, Chin TD, Gravelle CR. 1962. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am. J. Hyg. 76:173-95
219. WHO(WorldHealthOrgan.) 2007. Rabies vaccines:WHOposition paper. Wkly. Epidemiol. Rec. 82:425-35
220. Jiang B, Gentsch JR, Glass RI. 2002. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin. Infect. Dis. 34:1351-61
221. McNeal MM, Broome RL, Ward RL. 1994. Active immunity against rotavirus infection in mice is correlated with viral replication and titers of serum rotavirus IgA following vaccination. Virology 204:642-50
222. Matter L, Kogelschatz K, Germann D. 1997. Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J. Infect. Dis. 175:749-55
223. Skendzel LP. 1996. Rubella immunity. Defining the level of protective antibody. Am. J. Clin. Pathol. 106:170-74
224. Plotkin SA. 1995. Rubella vaccine. J. Infect. Dis. 171:1690-92
225. Fogel A, Gerichter CB, Barnea B, Handsher R, Heeger E. 1978. Response to experimental challenge in persons immunized with different rubella vaccines. J. Pediatr. 92:26-29
226. Mack TM, Noble J Jr, Thomas DB. 1972. A prospective study of serum antibody and protection against smallpox. Am. J. Trop. Med. Hyg. 21:214-18
227. Sarkar JK, Mitra AC, Mukherjee MK. 1975. The minimum protective level of antibodies in smallpox. Bull. World Health Organ. 52:307-11
228. White CJ, Kuter BJ, Ngai A, Hildebrand CS, Isganitis KL, et al. 1992. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr. Infect. Dis. J. 11:19-23
229. Clements DA, Armstrong CB, Ursano AM, Moggio MM, Walter EB,Wilfert CM. 1995. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatr. Infect. Dis. J. 14:874-79
230. MasonRA, TaurasoNM, Spertzel RO,GinnRK. 1973. Yellow fever vaccine: direct challenge ofmonkeys given graded doses of 17D vaccine. Appl. Microbiol. 25:539-44
231. Monath TP, Nichols R, Archambault WT,Moore L,Marchesani R, et al. 2002. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am. J. Trop. Med. Hyg. 66:533-41
232. Plotkin SA. 2001. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20:63-75
233. Plotkin SA. 2008. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47:401-9
234. Plotkin SA. 2010. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17:1055-65
235. Plotkin S, Orenstein WA, Offit P. 2012. Vaccines. Amsterdam: Elsevier
236. Amanna IJ, Messaoudi I, Slifka MK. 2008. Protective immunity following vaccination: How is it defined? Hum. Vaccin. 4:316-19